Drug intelligence / Profile preview

sulfaquinoxaline

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Sulfaquinoxaline is a synthetic small molecule veterinary drug belonging to the sulfonamide class. It is primarily used as an antiprotozoal and antibacterial agent for the prevention and treatment of coccidiosis in poultry (chickens, turkeys), cattle, sheep, and swine. It is also used to help control mortality from acute fowl cholera (caused by Pasteurella multocida) and fowl typhoid in chickens and turkeys[1][3][5]. Sulfaquinoxaline acts by inhibiting dihydropteroate synthetase, thereby blocking folic acid synthesis essential for nucleic acid formation in bacteria and protozoa such as Eimeria species[6][8]. Its peak activity against coccidia occurs at the second schizont stage of their life cycle[6]. The drug is minimally absorbed systemically when administered orally, acting mainly within the gastrointestinal tract[5]. Hemorrhagic syndrome can occur due to its interference with vitamin K metabolism in some animals on medicated feed[1][6].

Brand names
SUL-Q-NOX
Other names
sulfaquinoxalinesulfaquinoxaline sodium
02

Targets

DHPS (Dihydropteroate synthase)

Beyond the preview

Go deeper on sulfaquinoxaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sulfaquinoxaline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call